Literature DB >> 16688452

[18F]FETO: metabolic considerations.

Dagmar E Ettlinger1, Wolfgang Wadsak, Leonhard-Key Mien, Michael Machek, Leila Wabnegger, Gundula Rendl, Georgios Karanikas, Helmut Viernstein, Kurt Kletter, Robert Dudczak, Markus Mitterhauser.   

Abstract

PURPOSE: 11beta-Hydroxylase is a key enzyme in the biosynthesis of adrenocortical steroid hormones and is a suitable target for the imaging of the adrenal cortex. [(11)C]Metomidate (MTO), [(11)C]etomidate (ETO) and desethyl-[(18)F]fluoroethyl-etomidate (FETO) are potent inhibitors of this enzyme and are used for PET imaging of adrenocortical pathologies. The aims of this study were (1) to evaluate and compare the metabolic stability of MTO, ETO and FETO against esterases and (2) to investigate the metabolic pattern of FETO in vivo.
METHODS: In vitro assays were performed using different concentrations of MTO, ETO and FETO with constant concentrations of carboxylesterase. Human in vivo studies were performed with human blood samples drawn from the cubital vein. After sample clean-up, the serum was analysed by HPLC methods.
RESULTS: In vitro assays showed Michaelis-Menten constants of 115.1 mumol for FETO, 162.0 mumol for MTO and 168.6 mumol for ETO. Limiting velocities were 1.54 mumol/min (FETO), 1.47 mumol/min (MTO) and 1.35 mumol/min (ETO). This implies insignificantly decreased esterase stability of FETO compared with MTO and ETO. In vivo investigations showed a rapid metabolisation of FETO within the first 10 min (2 min: 91.41%+/-6.44%, n=6; 10 min: 23.78%+/-5.54%, n=4) followed by a smooth decrease in FETO from 20 to 90 min (20 min: 11.23%+/-3.79% n=4; 90 min: 3.68%+/-3.65%, n=4). Recovery rate was 61.43%+/-3.19% (n=12).
CONCLUSION: In vitro experiments demonstrated that FETO stability against esterases is comparable to that of ETO and MTO. The metabolic profile showed that FETO kinetics in humans are fast.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16688452     DOI: 10.1007/s00259-006-0123-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  6 in total

1.  [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers.

Authors:  Wolfgang Wadsak; Markus Mitterhauser; Gundula Rendl; Matthias Schuetz; Leonhard Key Mien; Dagmar E Ettlinger; Robert Dudczak; Kurt Kletter; Georgios Karanikas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

2.  Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.

Authors:  R Humerickhouse; K Lohrbach; L Li; W F Bosron; M E Dolan
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

3.  In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats.

Authors:  Markus Mitterhauser; Wolfgang Wadsak; Leila Wabnegger; Werner Sieghart; Helmut Viernstein; Kurt Kletter; Robert Dudczak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-03       Impact factor: 9.236

4.  Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.

Authors:  Georg Zettinig; Markus Mitterhauser; Wolfgang Wadsak; Alexander Becherer; Christian Pirich; Heinrich Vierhapper; Bruno Niederle; Robert Dudczak; Kurt Kletter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

5.  Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG.

Authors:  Heikki Minn; Anna Salonen; Johan Friberg; Anne Roivainen; Tapio Viljanen; Jaakko Långsjö; Jorma Salmi; Matti Välimäki; Kjell Någren; Pirjo Nuutila
Journal:  J Nucl Med       Date:  2004-06       Impact factor: 10.057

6.  11C-metomidate PET imaging of adrenocortical cancer.

Authors:  Tanweera S Khan; Anders Sundin; Claes Juhlin; Bengt Långström; Mats Bergström; Barbro Eriksson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-12-20       Impact factor: 9.236

  6 in total
  4 in total

Review 1.  11C-metomidate PET in the diagnosis of adrenal masses and primary aldosteronism: a review of the literature.

Authors:  Stanley M Chen Cardenas; Prasanna Santhanam
Journal:  Endocrine       Date:  2020-09-04       Impact factor: 3.633

Review 2.  Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT.

Authors:  Iosif A Mendichovszky; Andrew S Powlson; Roido Manavaki; Franklin I Aigbirhio; Heok Cheow; John R Buscombe; Mark Gurnell; Fiona J Gilbert
Journal:  Diagnostics (Basel)       Date:  2016-11-18

3.  Development of [18F]FAMTO: A novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands.

Authors:  Salvatore Bongarzone; Filippo Basagni; Teresa Sementa; Nisha Singh; Caleb Gakpetor; Vincent Faugeras; Jayanta Bordoloi; Antony D Gee
Journal:  Nucl Med Biol       Date:  2018-11-09       Impact factor: 2.408

4.  Autoradiography screening of potential positron emission tomography tracers for asymptomatic abdominal aortic aneurysms.

Authors:  Gustaf Tegler; Sergio Estrada; Håkan Hall; Anders Wanhainen; Martin Björck; Jens Sörensen; Gunnar Antoni
Journal:  Ups J Med Sci       Date:  2014-02-21       Impact factor: 2.384

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.